7H-吡喃并[2,3-d]嘧啶 | 254-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃嘧啶类
• 中文名称: 7H-吡喃并[2,3-d]嘧啶
• 英文名称: 7H-Pyrano[2,3-d]pyrimidine
• CAS: 254-69-3
• 化学式: C₇H₆N₂O
• 分子量: 134.14
• InChiKey: HFXRMQZCAIBURX-UHFFFAOYSA-N

物化性质

• 沸点：
  268.6±29.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
  申请人：Palani Anandan

  公开号：US20060264489A1

  公开（公告）日：2006-11-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

  具有通式（I）的一种化合物： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，其中： Q选自以下群组： 和 L选自以下群组： 或其药学上可接受的盐、溶剂化合物、酯或互变异构体，可用于治疗代谢综合征和血脂异常等疾病、疾患或症状。
• FLUORESCENT DYES, METHODS AND USES THEREOF
  申请人：Blackwell E. Helen

  公开号：US20070128658A1

  公开（公告）日：2007-06-07

  The present invention provides a method for identifying and characterizing candidate fluorescent molecules. This method involves the generation of spatially addressed arrays of heterocyclic compounds which are candidate fluorescent molecules. The spatially addressed array can be used to identify fluorescent molecules among the candidate molecules. The spatially addressed array can be used to determine the optical characteristics of one more candidate molecules. The invention also provides methods for making such arrays of heterocyclic compounds. In a specific embodiment, synthetic methods are provided for synthesis of triarylpyridines, particularly unsymmetric triarylpyridines. n preferred embodiments, the present invention provides novel heterocyclic fluorescent compounds having deazalumazine, cyanopyridine or pyrimidine cores. Heterocyclic fluorescent compounds of this invention are useful as dyes to label molecules such as nucleic acids, peptides and proteins, and particularly antibodies. In other embodiments, the novel heterocyclic fluorescent compounds are useful as dyes to label cellular compartments and organelles. The novel heterocyclic fluorescent compounds can also be used as sensors or indicators of specific metal ions, chemical warfare agents and pH.

  本发明提供了一种用于识别和表征候选荧光分子的方法。该方法涉及生成空间定位的杂环化合物阵列，这些化合物是候选荧光分子。空间定位的阵列可用于在候选分子中识别荧光分子。空间定位的阵列可用于确定一个或多个候选分子的光学特性。该发明还提供了制备这种杂环化合物阵列的方法。在一个具体实施例中，提供了合成三芳基吡啶的合成方法，特别是非对称的三芳基吡啶。在首选实施例中，本发明提供了具有脱阿拉木青、氰基吡啶或嘧啶核的新型杂环荧光化合物。本发明的这些杂环荧光化合物可用作染料，用于标记核酸、肽和蛋白质，尤其是抗体。在其他实施例中，这些新型杂环荧光化合物可用作染料，用于标记细胞区室和细胞器。这些新型杂环荧光化合物还可用作特定金属离子、化学战剂和pH的传感器或指示剂。
• 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040224951A1

  公开（公告）日：2004-11-11

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 5 , Y 6 , Y 8 , R 2 , R 4 , and R 7 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、Y5、Y6、Y8、R2、R4和R7如规范中所定义。本发明还提供了包括公式I中定义的化合物或其药学上可接受的盐的制药组合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予公式I中定义的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者体内给予公式I中定义的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎、除骨关节炎或类风湿性关节炎外的其他关节炎、心力衰竭、炎症性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予公式I中定义的化合物或其药学上可接受的盐，单独或与制药组合物一起。本发明还提供了包括公式I中定义的化合物或其药学上可接受的盐和规范中描述的另一种药学活性成分的组合物。
• Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040063673A1

  公开（公告）日：2004-04-01

  This invention provides compounds defined by Formula I Z—L—R 1 —Q—D—(V 1 ) m —R 2 I or a pharmaceutically acceptable salt thereof, wherein Z, L, R 1 , Q, D, V 1 , m, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由式子IZ—L—R1—Q—D—（V1）m—R2或其药学上可接受的盐所定义的化合物，其中Z，L，R1，Q，D，V1，m和R2在规范中有定义。本发明还提供了制药组合物，包括由规范中定义的式子I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MMP-13酶的方法，包括向动物投与式子I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗患有由MMP-13酶介导的疾病的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎症性肠病、老年性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的患者的方法，包括向患者投与式子I或其药学上可接受的盐所定义的化合物，单独使用或在制药组合物中使用。本发明还提供了由式子I或其药学上可接受的盐所定义的化合物与规范中描述的另一种药物活性成分的组合。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Palani Anandan

  公开号：US20080019978A1

  公开（公告）日：2008-01-24

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）的化合物及其药学上可接受的盐，溶剂化合物，酯和互变异构体，其中： Q选自以下组： L选自以下组： 本发明还提供了包含一种或多种式（I）化合物的药学组合物以及使用式（I）化合物的方法。